Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 704 (ZNF704) is a nuclear, sequence-specific DNA-binding protein that acts as a transcription factor, regulating gene expression via RNA polymerase II. ZNF704 physically interacts with the SIN3A corepressor complex (including SIN3A, SAP130, HDAC1, HDAC2, and RBBP4) and contributes to the transcriptional repression of target genes. It is variably expressed across tissues, mainly localizing to the nucleus. ZNF704 has been implicated in oncogenic processes, with overexpression associated with poor prognosis and increased cell proliferation in chondrosarcoma, breast cancer, prostate cancer, and uveal melanoma. Mechanistically, ZNF704 activates the PI3K/AKT/mTOR pathway in some cancers. With its strong association with several tumor types and influence on cell growth and apoptosis, ZNF704 is an emerging biomarker and potential therapeutic target in oncology.
Not directly applicable since no specific drugs are known to target ZNF704; hypothetical mechanism would involve inhibition or modulation of transcriptional activity, potentially via disruption of its interaction with SIN3A or DNA binding
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 704 (ZNF704).